Table 1.
Clinical and demographic factors between TNF antagonist responders and non-responders.
| Clinical factors | Anti-TNF responders [n= 433] | Anti-TNF non-responders [n= 41] | OR [95% CI] p-Value | Adjusted OR [95% CI] p-Value |
|---|---|---|---|---|
| Sex, male, no. [%] | 184 [42.5] | 12 [29.3] | 0.55 [0.27–1.11] | -- |
| p = 0.09 | ||||
| Age at diagnosis, years [SD] | 29.8 [13.4] | 26.4 [12.1] | 1.35 [0.70–2.58] | -- |
| <25 years, no. [%] | 178 [41.1] | 20 [48.8] | p = 0.37 | |
| Disease duration, years [SD] | 11.9 [9.1] | 12.5 [7.4] | p = 0.71 | -- |
| Family history of IBD, no. [%] | 68 [15.7] | 5 [12.2] | 0.75 [0.28–1.97] | -- |
| p = 0.50 | ||||
| Smoking at diagnosis, no. [%] | 74 [17.1] | 8 [19.5] | 1.18 [0.5–2.64] | -- |
| p = 0.70 | ||||
| IBD phenotype, no. [%] | p = 0.70 | -- | ||
| CD | 327 [75.5] | 32 [78.0] | ||
| UC | 91 [21.0] | 8 [19.5] | ||
| IC | 15 [3.5] | 1 [2.4] | ||
| Immunomodulator, no. [%] | 339 [78.3] | 41 [100] | 10.7 [1.46–79.1] | 10.2 [1.38–75.00] |
| p = 5.0E-04 | p = 8.73E-04 | |||
| Bowel resection, no. [%] | 137 [31.6] | 25 [61.0] | 3.38 [1.75–6.53] | 3.24 [1.67–6.30] |
| p = 2.42E-04 | p = 4.38E-04 | |||
| Advanced IBD behaviour [stricturing/penetrating, extensive colitis], no. [%] | 245 [56.6] | 26 [63.4] | 1.32 [0.67–2.60] | -- |
| p = 0.42 | ||||
| Perianal abscess/fistula, no. [%] | 74 [17.1] | 10 [24.4] | 1.78 [0.82–3.84] | -- |
| p = 0.16 | ||||
| Extra-GI manifestation, no. [%] | p = 0.28 | |||
| Eye | 17 [3.9] | 3 [7.3] | p = 0.13 | -- |
| Skin | 19 [4.4] | 4 [9.8] | p = 0.75 | -- |
| Joint | 83 [19.2] | 8 [19.5] | p = 0.66 | -- |
| PSC | 7 [1.6] | 1 [2.4] | -- |
OR >1.00 suggests no response to anti-TNF agent.
CD, Crohn’s disease; GI, gastrointestinal; IBD, inflammatory bowel disease; IC, indeterminate colitis; OR, odds ratio; PSC, primary sclerosing cholangitis; TNF, tumour necrosis factor; UC, ulcerative colitis; CI, confidence interval; SD, standard deviation; GI, gastrointestinal..